Beneficial effect of synbiotic supplementation on hepatic steatosis and anthropometric parameters, but not on gut permeability in a population with nonalcoholic steatohepatitis

Nutrients

Volumn 8, Issue 7, 2016, Pages

  Ferolla, Silvia M ^a   Couto, Cláudia A ^a   Costa Silva, Luciana ^a   Armiliato, Geyza N A ^a   Pereira, Cristiano A S ^a   Martins, Flaviano S ^a   Ferrari, Maria de Lourdes A ^a   Vilela, Eduardo G ^a   Torres, Henrique O G ^a   Cunha, Aloísio S ^a   Ferrari, Teresa C A ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Gut microbiota; Hepatic steatosis; Intestinal permeability; Lipopolysaccharide; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Obesity; Probiotic; Synbiotic; Weight loss

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; GUAR GUM; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INULIN; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SYNBIOTIC AGENT; TRIACYLGLYCEROL; URIC ACID; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANTHROPOMETRY; ARTICLE; BACTERIAL OVERGROWTH; BODY MASS; BREATH ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FATTY LIVER; FEMALE; GLUCOSE BREATH TEST; GUT PERMEABILITY; HUMAN; INTESTINE FUNCTION; LACTOBACILLUS REUTERI; MALE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL ASSESSMENT; NUTRITIONAL COUNSELING; OUTCOME ASSESSMENT; SMALL INTESTINE; SUPPLEMENTATION; URINARY EXCRETION; WAIST CIRCUMFERENCE; AGED; BLOOD; INTESTINE; INTESTINE FLORA; LIVER; METABOLISM; MICROBIOLOGY; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PERMEABILITY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BODY MASS INDEX; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; INTESTINES; LIPOPOLYSACCHARIDES; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PERMEABILITY; SYNBIOTICS; WAIST CIRCUMFERENCE;

EID: 85015987394     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu8070397     Document Type: Article

References (106)

1. Byrne, C.D.; Targher, G. NAFLD: A multisystem disease. J. Hepatol. 2015, 62, S47-S64. [CrossRef] [PubMed]
2. Rozman, D. From nonalcoholic Fatty liver disease to hepatocellular carcinoma: A systems understanding. Dig. Dis. Sci. 2014, 59, 238-241. [CrossRef] [PubMed]
3. Armstrong, M.J.; Adams, L.A.; Canbay, A.; Syn,W.K. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 2014, 59, 1174-1197. [CrossRef] [PubMed]
4. Arendt, B.M.; Allard, J.P. Effect of atorvastatin, vitamin E and C on nonalcoholic fatty liver disease: Is the combination required? Am. J. Gastroenterol. 2011, 106, 78-80. [CrossRef] [PubMed]
5. Bell, L.N.; Wang, J.; Muralidharan, S.; Chalasani, S.; Fullenkamp, A.M.; Wilson, L.A.; Sanyal, A.J.; Kowdley, K.V.; Neuschwander-Tetri, B.A.; Brunt, E.M.; et al. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: A pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. Hepatology 2012, 56, 1311-1318. [CrossRef] [PubMed]
6. Pamuk, G.E.; Sonsuz, A. N-acetylcysteine in the treatment of non-alcoholic steatohepatitis. J. Gastroenterol. Hepatol. 2003, 18, 1220-1221. [CrossRef] [PubMed]
7. Ratziu, V.; de Ledinghen, V.; Oberti, F.; Mathurin, P.; Wartelle-Bladou, C.; Renou, C.; Sogni, P.; Maynard, M.; Larrey, D.; Serfaty, L.; et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J. Hepatol. 2011, 54, 1011-1019. [CrossRef] [PubMed]
8. Shargorodsky, M.; Omelchenko, E.; Matas, Z.; Boaz, M.; Gavish, D. Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: Effects beyond glucose lowering? Cardiovasc. Diabetol. 2012, 11, 61. [CrossRef] [PubMed]
9. Zein, C.O.; Lopez, R.; Fu, X.; Kirwan, J.P.; Yerian, L.M.; McCullough, A.J.; Hazen, S.L.; Feldstein, A.E. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: New evidence on the potential therapeutic mechanism. Hepatology 2012, 56, 1291-1299. [CrossRef] [PubMed]
10. Machado, M.V.; Cortez-Pinto, H. Non-alcoholic fatty liver disease: What the clinician needs to know. World J. Gastroenterol. 2014, 20, 12956-12980. [CrossRef] [PubMed]
11. Chalasani, N.; Younossi, Z.; Lavine, J.E.; Diehl, A.M.; Brunt, E.M.; Cusi, K.; Charlton, M.; Sanyal, A.J. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55, 2005-2023. [CrossRef] [PubMed]
12. Day, C.P. Pathogenesis of steatohepatitis. Best Pract. Res. Clin. Gastroenterol. 2002, 16, 663-678. [CrossRef] [PubMed]
13. Kojima, H.; Sakurai, S.; Uemura, M.; Fukui, H.; Morimoto, H.; Tamagawa, Y. Mitochondrial abnormality and oxidative stress in nonalcoholic steatohepatitis. Alcohol. Clin. Exp. Res. 2007, 31, S61-S66. [CrossRef] [PubMed]
14. Dai, X.; Wang, B. Role of gut barrier function in the pathogenesis of nonalcoholic Fatty liver disease. Gastroenterol. Res. Pract. 2015, 2015, 287348. [CrossRef] [PubMed]
15. Nair, S.; Cope, K.; Risby, T.H.; Diehl, A.M. Obesity and female gender increase breath ethanol concentration: Potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2001, 96, 1200-1204. [CrossRef] [PubMed]
16. Iacono, A.; Raso, G.M.; Canani, R.B.; Calignano, A.; Meli, R. Probiotics as an emerging therapeutic strategy to treat NAFLD: Focus on molecular and biochemical mechanisms. J. Nutr. Biochem. 2011, 22, 699-711. [CrossRef] [PubMed]
17. Aller, R.; de Luis, D.A.; Izaola, O.; Conde, R.; Gonzalez Sagrado, M.; Primo, D.; de la Fuente, B.; Gonzalez, J. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind randomized clinical trial. Eur. Rev. Med. Pharmacol. Sci. 2011, 15, 1090-1095. [PubMed]
18. Eslamparast, T.; Poustchi, H.; Zamani, F.; Sharafkhah, M.; Malekzadeh, R.; Hekmatdoost, A. Synbiotic supplementation in nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled pilot study. Am. J. Clin. Nutr. 2014, 99, 535-542. [CrossRef] [PubMed]
19. Loguercio, C.; de Simone, T.; Federico, A.; Terracciano, F.; Tuccillo, C.; di Chicco, M.; Cartenì, M. Gut-liver axis: A new point of attack to treat chronic liver damage? Am. J. Gastroenterol. 2002, 97, 2144-2146. [CrossRef] [PubMed]
20. Loguercio, C.; Federico, A.; Tuccillo, C.; Terracciano, F.; D'Auria, M.V.; de Simone, C.; del Vecchio Blanco, C. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J. Clin. Gastroenterol. 2005, 39, 540-543. [PubMed]
21. Malaguarnera, M.; Vacante, M.; Antic, T.; Giordano, M.; Chisari, G.; Acquaviva, R.; Mastrojeni, S.; Malaguarnera, G.; Mistretta, A.; Li Volti, G. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig. Dis. Sci. 2012, 57, 545-553. [CrossRef] [PubMed]
22. Vajro, P.; Mandato, C.; Licenziati, M.R.; Franzese, A.; Vitale, D.F.; Lenta, S.; Caropreso, M.; Vallone, G.; Meli, R. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J. Pediatr. Gastroenterol. Nutr. 2011, 52, 740-743. [CrossRef] [PubMed]
23. Wong, V.W.; Won, G.L.; Chim, A.M.; Chu, W.C.; Yeung, D.K.; Li, K.C.; Chan, H.L. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann. Hepatol. 2013, 12, 256-262. [PubMed]
24. Gerritsen, J.; Smidt, H.; Rijkers, G.T.; de Vos, W.M. Intestinal microbiota in human health and disease: The impact of probiotics. Genes Nutr. 2011, 6, 209-240. [CrossRef] [PubMed]
25. Fak, F.; Backhed, F. Lactobacillus reuteri prevents diet-induced obesity, but not atherosclerosis, in a strain dependent fashion in Apoe-/-mice. PLoS ONE 2012, 7, e46837. [CrossRef] [PubMed]
26. Poutahidis, T.; Kleinewietfeld, M.; Smillie, C.; Levkovich, T.; Perrotta, A.; Bhela, S.; Varian, B.J.; Ibrahim, Y.M.; Lakritz, J.R.; Kearney, S.M.; et al. Microbial reprogramming inhibits Western diet-associated obesity. PLoS ONE 2013, 8, e68596. [CrossRef] [PubMed]
27. Tsurumaki, M.; Kotake, M.; Iwasaki, M.; Saito, M.; Tanaka, K.; Aw,W.; Fukuda, S.; Tomita, M. The application of omics technologies in the functional evaluation of inulin and inulin-containing prebiotics dietary supplementation. Nutr. Diabetes 2015, 5, e185. [CrossRef] [PubMed]
28. Slavin, J. Fiber and Prebiotics: Mechanisms and Health Benefits. Nutrients 2013, 5, 1417-1435. [CrossRef] [PubMed]
29. Giannini, E.G.; Mansi, C.; Dulbecco, P.; Savarino, V. Role of partially hydrolyzed guar gum in the treatment of irritable bowel syndrome. Nutrition 2006, 22, 334-342. [CrossRef] [PubMed]
30. Kleiner, D.E.; Brunt, E.M.; van Natta, M.; Behling, C.; Contos, M.J.; Cummings, O.W.; Ferrell, L.D.; Liu, Y.C.; Torbenson, M.S.; Unalp-Arida, A.; et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41, 1313-1321. [CrossRef] [PubMed]
31. Matthews, D.R.; Hosker, J.P.; Rudenski, A.S.; Naylor, B.A.; Treacher, D.F.; Turner, R.C. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28, 412-419. [CrossRef] [PubMed]
32. Angulo, P.; Hui, J.M.; Marchesini, G.; Bugianesi, E.; George, J.; Farrell, G.C.; Enders, F.; Saksena, S.; Burt, A.D.; Bida, J.P.; et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007, 45, 846-854. [CrossRef] [PubMed]
33. Alberti, K.G.; Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z.; Cleeman, J.I.; Donato, K.A.; Fruchart, J.C.; James, W.P.; Loria, C.M.; Smith, S.C., Jr.; et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120, 1640-1645. [PubMed]
34. Alberti, K.G.; Zimmet, P.; Shaw, J. Group IDFETFC. The metabolic syndrome-a new worldwide definition. Lancet 2005, 366, 1059-1062. [CrossRef]
35. Gallagher, D.; Heymsfield, S.B.; Heo, M.; Jebb, S.A.; Murgatroyd, P.R.; Sakamoto, Y. Healthy percentage body fat ranges: An approach for developing guidelines based on body mass index. Am. J. Clin. Nutr. 2000, 72, 694-701. [PubMed]
36. Oliveros, E.; Somers, V.K.; Sochor, O.; Goel, K.; Lopez-Jimenez, F. The concept of normal weight obesity. Progress Cardiovasc. Dis. 2014, 56, 426-433. [CrossRef] [PubMed]
37. Bydder, M.; Yokoo, T.; Hamilton, G.; Middleton, M.S.; Chavez, A.D.; Schwimmer, J.B.; Lavine, J.E.; Sirlin, C.B. Relaxation effects in the quantification of fat using gradient echo imaging. Magn. Reson. Imaging 2008, 26, 347-359. [CrossRef] [PubMed]
38. Hines, C.D.; Frydrychowicz, A.; Hamilton, G.; Tudorascu, D.L.; Vigen, K.K.; Yu, H.; McKenzie, C.A.; Sirlin, C.B.; Brittain, J.H.; Reeder, S.B. T(1) independent, T(2) (*) corrected chemical shift based fat-water separation with multi-peak fat spectral modeling is an accurate and precise measure of hepatic steatosis. J. Magn. Reson. Imaging 2011, 33, 873-881. [CrossRef] [PubMed]
39. Hines, C.D.; Yu, H.; Shimakawa, A.; McKenzie, C.A.; Warner, T.F.; Brittain, J.H.; McKenzie, C.A.; Sirlin, C.B.; Brittain, J.H.; Reeder, S.B. Quantification of hepatic steatosis with 3-T MR imaging: Validation in ob/ob mice. Radiology 2010, 254, 119-128. [CrossRef] [PubMed]
40. Idilman, I.S.; Aniktar, H.; Idilman, R.; Kabacam, G.; Savas, B.; Elhan, A.; Celik, A.; Bahar, K.; Karcaaltincaba, M. Hepatic steatosis: Quantification by proton density fat fraction with MR imaging versus liver biopsy. Radiology 2013, 267, 767-775. [CrossRef] [PubMed]
41. Meisamy, S.; Hines, C.D.; Hamilton, G.; Sirlin, C.B.; McKenzie, C.A.; Yu, H.; Brittain, J.H.; Reeder, S.B. Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: Blinded comparison with MR spectroscopy. Radiology 2011, 258, 767-775. [CrossRef] [PubMed]
42. Reeder, S.B.; Cruite, I.; Hamilton, G.; Sirlin, C.B. Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy. J. Magn. Reson. Imaging 2011, 34, 729-749. [CrossRef] [PubMed]
43. Yokoo, T.; Shiehmorteza, M.; Hamilton, G.; Wolfson, T.; Schroeder, M.E.; Middleton, M.S.; Bydder, M.; Gamst, A.C.; Kono, Y.; Kuo, A.; et al. Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T. Radiology 2011, 258, 749-759. [CrossRef] [PubMed]
44. Zhong, X.; Nickel, M.D.; Kannengiesser, S.A.; Dale, B.M.; Kiefer, B.; Bashir, M.R. Liver fat quantification using a multi-step adaptive fitting approach with multi-echo GRE imaging. Magn. Reson. Med. 2014, 72, 1353-1365. [CrossRef] [PubMed]
45. Tang, A.; Desai, A.; Hamilton, G.; Wolfson, T.; Gamst, A.; Lam, J.; Clark, L.; Hooker, J.; Chavez, T.; Ang, B.D.; et al. Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology 2015, 274, 416-425. [CrossRef] [PubMed]
46. Koplay, M.; Sivri, M.; Erdogan, H.; Nayman, A. Importance of imaging and recent developments in diagnosis of nonalcoholic fatty liver disease. World J. Hepatol. 2015, 7, 769-776. [CrossRef] [PubMed]
47. Tang, A.; Tan, J.; Sun, M.; Hamilton, G.; Bydder, M.;Wolfson, T.; Gamst, A.C.; Middleton, M.; Brunt, E.M.; Loomba, R.; et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology 2013, 267, 422-431. [CrossRef] [PubMed]
48. Yokoo, T.; Bydder, M.; Hamilton, G.; Middleton, M.S.; Gamst, A.C.; Wolfson, T.; Hassanein, T.; Patton, H.M.; Lavine, J.E.; Schwimmer, J.B.; et al. Nonalcoholic fatty liver disease: Diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology 2009, 251, 67-76. [CrossRef] [PubMed]
49. Chen, J.; Talwalkar, J.A.; Yin, M.; Glaser, K.J.; Sanderson, S.O.; Ehman, R.L. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 2011, 259, 749-756. [CrossRef] [PubMed]
50. Yin, M.; Talwalkar, J.A.; Glaser, K.J.; Manduca, A.; Grimm, R.C.; Rossman, P.J.; Fidler, J.L.; Ehman, R.L. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin. Gastroenterol. Hepatol. 2007, 5, 1207-1213. [CrossRef] [PubMed]
51. Vilela, E.G.; Ferrari, M.L.A.; Torres, H.O.G.; Pinto, A.G.; Aguirre, A.C.C.; Martins, F.P.; Goulart, E.M.A.; Cunha, A.S. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand. J. Gastroenterol. 2008, 43, 842-848. [CrossRef] [PubMed]
52. Travis, S.; Menzies, I. Intestinal permeability: Functional assessment and significance. Clin. Sci. 1992, 82, 471-488. [CrossRef] [PubMed]
53. Vilela, E.G.; Ataliba, G.S.; Torres, H.O.G.; Ferrari, M.L.A.; Cunha, A.S. Intestinal permeability measurement in healthy subjects: Standartizationof technique and analysis of results. Int. J. Inflamm. Bowel Dis. 2015, 2, 57-61.
54. Kerlin, P.; Wrong, I. Breath hydrogen testing in bacterial overgrowth of the small intestine. Gastroenterology 1988, 95, 982-988. [CrossRef]
55. Holanda, L.B.; Filho, A.A.B. Métodosaplicadoseminquéritosalimentares. Rev. Paul. Pediatr. 2006, 24, 62-70.
56. Núcleo de Estudos e PesquisaemAlimentação. TabelaBrasileira de Composição de Alimentos/NEPA-UNICAMP, 4th ed.; Book Editora: Campinas, Brazil, 2011; pp. 1-161.
57. Bellentani, S.; Dalle, R.G.; Suppini, A.; Marchesini, G. Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. Hepatology 2008, 47, 746-754. [CrossRef] [PubMed]
58. Departamento de AtençãoBásica, Secretaria de Atenção à Saúde, Ministério da Saúde. GuiaAlimentar Para a PopulaçãoBrasileira: PromovendoaAlimentaçãoSaudável/Ministério da Saúde, Secretaria de Saúde,Departamento de AtençãoBásica; Ministério da Saúde: Brasília, Brazil, 2005; pp. 1-210.
59. Haskell, W.L.; Lee, I.M.; Pate, R.R.; Powell, K.E.; Blair, S.N.; Franklin, B.A.; Macera, C.A.; Heath, G.W.; Thompson, P.D.; Bauman, A.; et al. Physical activity and public health: Updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation 2007, 116, 1081-1093. [PubMed]
60. Chen, Y.; Wang, X.; Wang, J.; Yan, Z.; Luo, J. Excess body weight and the risk of primary liver cancer: An updated meta-analysis of prospective studies. Eur. J. Cancer 2012, 48, 2137-2145. [CrossRef] [PubMed]
61. Nazare, J.A.; Smith, J.; Borel, A.L.; Aschner, P.; Barter, P.; van Gaal, L.; Tan, C.E.; Wittchen, H.U.; Matsuazawa, Y.; Kadowaki, T.; et al. Usefulness of measuring both body mass index and waist circumference for the estimation of visceral adiposity and related cardiometabolic risk profile (from the INSPIRE ME IAA study). Am. J. Cardiol. 2015, 115, 307-315. [CrossRef] [PubMed]
62. Cheung, O.; Kapoor, A.; Puri, P.; Sistrun, S.; Luketic, V.A.; Sargeant, C.C.; Contos, M.J.; Shiffman, M.L.; Stravitz, R.T.; Sterling, R.K.; et al. The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology 2007, 46, 1091-1100. [CrossRef] [PubMed]
63. Ratziu, V.; Giral, P.; Charlotte, F.; Bruckert, E.; Thibault, V.; Theodorou, I.; Khalil, L.; Turpin, G.; Opolon, P.; Poynard, T. Liver fibrosis in overweight patients. Gastroenterology 2000, 118, 1117-1123. [CrossRef]
64. Ande, S.R.; Nguyen, K.H.; Grégoire Nyomba, B.L.; Mishra, S. Prohibitin-induced, obesity-associated insulin resistance and accompanying low-grade inflammation causes NASH and HCC. Sci. Rep. 2016, 23, 23608. [CrossRef] [PubMed]
65. Kadooka, Y.; Sato, M.; Imaizumi, K.; Ogawa, A.; Ikuyama, K.; Akai, Y.; Okano, M.; Kagoshima, M.; Tsuchida, T. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. Eur. J. Clin. Nutr. 2010, 64, 636-643. [CrossRef] [PubMed]
66. Ley, R.E.; Turnbaugh, P.J.; Klein, S.; Gordon, J.I. Microbial ecology: Human gut microbes associated with obesity. Nature 2006, 444, 1022-1023. [CrossRef] [PubMed]
67. Turnbaugh, P.J.; Ley, R.E.; Mahowald, M.A.; Magrini, V.; Mardis, E.R.; Gordon, J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444, 1027-1031. [CrossRef] [PubMed]
68. Caricilli, A.M.; Saad, M.J. The role of gut microbiota on insulin resistance. Nutrients 2013, 5, 829-851. [CrossRef] [PubMed]
69. Duseja, A.; Chawla, Y.K. Obesity and NAFLD: The role of bacteria and microbiota. Clin. Liver Dis. 2014, 18, 59-71. [CrossRef] [PubMed]
70. Rychlik, J.L.; May, T. The effect of a methanogen, Methanobrevibacter smithii, on the growth rate, organic acid production, and specific ATP activity of three predominant ruminal cellulolytic bacteria. Curr. Microbiol. 2000, 40, 176-180. [CrossRef] [PubMed]
71. Mouzaki, M.; Comelli, E.M.; Arendt, B.M.; Bonengel, J.; Fung, S.K.; Fischer, S.E.; McGilvray, I.D.; Allard, J.P. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 2013, 58, 120-127. [CrossRef] [PubMed]
72. Ohashi, Y.; Sumitani, K.; Tokunaga, M.; Ishihara, N.; Okubo, T.; Fujisawa, T. Consumption of partially hydrolysed guar gum stimulates Bifidobacteria and butyrate-producing bacteria in the human large intestine. Benef. Microbes 2015, 6, 451-455. [CrossRef] [PubMed]
73. Sato, M.; Uzu, K.; Yoshida, T.; Hamad, E.M.; Kawakami, H.; Matsuyama, H.; Abd El-Gawad, I.A.; Imaizumi, K. Effects of milk fermented by Lactobacillus gasseri SBT2055 on adipocyte size in rats. Br. J. Nutr. 2008, 99, 1013-1017. [CrossRef] [PubMed]
74. Hamad, E.M.; Sato, M.; Uzu, K.; Yoshida, T.; Higashi, S.; Kawakami, H.; Kadooka, Y.; Matsuyama, H.; Abd El-Gawad, I.A.; Imaizumi, K. Milk fermented by Lactobacillus gasseri SBT2055 influences adipocyte size via inhibition of dietary fat absorption in Zucker rats. Br. J. Nutr. 2009, 101, 716-724. [CrossRef] [PubMed]
75. Anders, A.J.; van den Borne, J.J.; de Graaf, C.; Hulshof, T.; Jonathan, M.C.; Kristensen, M.; Mars, M.; Schols, H.A.; Feskens, E.J. Effects of dietary fibre on subjective appetite, energy intake and body weight: A systematic review of randomized controlled trials. Obes. Rev. 2011, 12, 724. [CrossRef] [PubMed]
76. Birketvedt, G.S.; Shimshi, M.; Erling, T.; Florholmen, J. Experiences with three different fiber supplements in weight reduction. Med. Sci. Monit. 2005, 11, I5-I8.
77. Pittler, M.H.; Ernst, E. Dietary supplements for body-weight reduction: A systematic review. Am. J. Clin. Nutr. 2004, 79, 529-536. [PubMed]
78. Liber, A.; Szajewska, H. Effect of oligofructose supplementation on body weight in overweight and obese children: A randomised, double-blind, placebo-controlled trial. Br. J. Nutr. 2014, 112, 2068-2074. [CrossRef] [PubMed]
79. Lyon, M.; Wood, S.; Pelletier, X.; Donazzolo, Y.; Gahler, R.; Bellisle, F. Effects of a 3-month supplementation with a novel soluble highly viscous polysaccharide on anthropometry and blood lipids in nondieting overweight or obese adults. J. Hum. Nutr. Diet. 2011, 24, 351-359. [CrossRef] [PubMed]
80. Brockman, D.A.; Chen, X.; Gallaher, D.D. High-viscosity dietary fibers reduce adiposity and decrease hepatic steatosis in rats fed a high-fat diet. J. Nutr. 2014, 144, 1415-1422. [CrossRef] [PubMed]
81. Guess, N.D.; Dornhorst, A.; Oliver, N.; Bell, J.D.; Thomas, E.L.; Frost, G.S. A randomized controlled trial: The effect of inulin on weight management and ectopic fat in subjects with prediabetes. Nutr. Metab. 2015, 12, 36. [CrossRef] [PubMed]
82. Lee, Y.J.; Lee, H.R.; Lee, J.H.; Shin, Y.H.; Shim, J.Y. Association between serum uric acid and non-alcoholic fatty liver disease in Korean adults. Clin. Chem. Lab. Med. 2010, 48, 175-180. [CrossRef] [PubMed]
83. Hwang, I.C.; Suh, S.Y.; Suh, A.R.; Ahn, H.Y. The relationship between normal serum uric acid and nonalcoholic fatty liver disease. J. Korean Med. Sci. 2011, 26, 386-391. [CrossRef] [PubMed]
84. Feig, D.I.; Kang, D.H.; Johnson, R.J. Uric acid and cardiovascular risk. N. Engl. J. Med. 2008, 359, 1811-1821. [CrossRef] [PubMed]
85. Ruan, Y.; Sun, J.; He, J.; Chen, F.; Chen, R.; Chen, H. Effect of Probiotics on Glycemic Control: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials. PLoS ONE 2015, 10, e0132121. [CrossRef] [PubMed]
86. Abd El-KaderEman, S.M.; El-Den Ashmawy, S.M. Non-alcoholic fatty liver disease: The diagnosis and management. World J. Hepatol. 2015, 7, 846-858.
87. Miele, L.; Valenza, V.; La Torre, G.; Montalto, M.; Cammarota, G.; Ricci, R.; Mascianà, R.; Forgione, A.; Gabrieli, M.L.; Perotti, G. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009, 49, 1877-1887. [CrossRef] [PubMed]
88. Volynets, V.; Küper, M.A.; Strahl, S.; Maier, I.B.; Spruss, A.; Wagnerberger, S.; Königsrainer, A.; Bischoff, S.C.; Bergheim, I. Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). Dig. Dis. Sci. 2012, 57, 1932-1941. [CrossRef] [PubMed]
89. Aoyama, T.; Paik, Y.H.; Seki, E. Toll-like receptor signaling and liver fibrosis. Gastroenterol. Res. Pract. 2010, 2010. [CrossRef] [PubMed]
90. Bugianesi, E.; Gastaldelli, A.; Vanni, E.; Gambino, R.; Cassader, M.; Baldi, S.; Ponti, V.; Pagano, G.; Ferrannini, E.; Rizzetto, M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: Sites and mechanisms. Diabetologia 2005, 48, 634-642. [CrossRef] [PubMed]
91. Horton, J.D.; Goldstein, J.L.; Brown, M.S. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Investig. 2002, 109, 1125-1131. [CrossRef] [PubMed]
92. Sabate, J.M.; Jouet, P.; Harnois, F.; Mechler, C.; Msika, S.; Grossin, M.; Coffin, B. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: A contributor to severe hepatic steatosis. Obes. Surg. 2008, 18, 371-377. [CrossRef] [PubMed]
93. Sajjad, A.; Mottershead, M.; Syn,W.K.; Jones, R.; Smith, S.; Nwokolo, C.U. Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2005, 22, 291-299. [CrossRef] [PubMed]
94. Shanab, A.A.; Scully, P.; Crosbie, O.; Buckley, M.; O'Mahony, L.; Shanahan, F.; Gazareen, S.; Murphy, E.; Quigley, E.M. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: Association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig. Dis. Sci. 2011, 56, 1524-1534. [CrossRef] [PubMed]
95. Wigg, A.J.; Roberts-Thomson, I.C.; Dymock, R.B.; McCarthy, P.J.; Grose, R.H.; Cummins, A.G. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001, 48, 206-211. [CrossRef] [PubMed]
96. Riordan, S.M.; Duncombe, V.M.; Thomas, M.C.; Nagree, A.; Bolin, T.D.; McIver, C.J.; Williams, R. Small intestinal bacterial overgrowth, intestinal permeability, and non-alcoholic steatohepatitis. Gut 2002, 50, 136-138. [CrossRef] [PubMed]
97. Berer, K.; Mues, M.; Koutrolos, M.; Rasbi, Z.A.; Boziki, M.; Johner, C.; Wekerle, H.; Krishnamoorthy, G. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 2011, 479, 538-541. [CrossRef] [PubMed]
98. Claesson, M.J.; Jeffery, I.B.; Conde, S.; Power, S.E.; O'Connor, E.M.; Cusack, S.; Harris, H.M.; Coakley, M.; Lakshminarayanan, B.; O'Sullivan, O.; et al. Gut microbiota composition correlates with diet and health in the elderly. Nature 2012, 488, 178-184. [CrossRef] [PubMed]
99. Erdman, S.E.; Rao, V.P.; Olipitz, W.; Taylor, C.L.; Jackson, E.A.; Levkovich, T.; Lee, C.W.; Horwitz, B.H.; Fox, J.G.; Ge, Z.; et al. Unifying roles for regulatory T cells and inflammation in cancer. Int. J. Cancer 2010, 126, 1651-1665. [CrossRef] [PubMed]
100. Flint, H.J.; Scott, K.P.; Louis, P.; Duncan, S.H. The role of the gut microbiota in nutrition and health. Nat. Rev. Gastroenterol. Hepatol. 2012, 9, 577-589. [CrossRef] [PubMed]
101. Hooper, L.V.; Littman, D.R.; Macpherson, A.J. Interactions between the microbiota and the immune system. Science 2012, 336, 1268-1273. [CrossRef] [PubMed]
102. Maynard, C.L.; Elson, C.O.; Hatton, R.D.;Weaver, C.T. Reciprocal interactions of the intestinal microbiota and immune system. Nature 2012, 489, 231-241. [CrossRef] [PubMed]
103. Shoelson, S.E.; Herrero, L.; Naaz, A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007, 132, 2169-2180. [CrossRef] [PubMed]
104. Alisi, A.; Bedogni, G.; Baviera, G.; Giorgio, V.; Porro, E.; Paris, C.; Giammaria, P.; Reali, L.; Anania, F.; Nobili, V. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2014, 39, 1276-1285. [PubMed]
105. Mykhal'chyshyn, H.P.; Bodnar, P.M.; Kobyliak, N.M. Effect of probiotics on proinflammatory cytokines level in patients with type 2 diabetes and nonalcoholic fatty liver disease. Likars'ka Sprava 2013, 2, 56-62. [PubMed]
106. Solga, S.F.; Buckley, G.; Clark, J.M.; Horska, A.; Diehl, A.M. The effect of a probiotic on hepatic steatosis. J. Clin. Gastroenterol. 2008, 42, 1117-1119. [CrossRef] [PubMed]